Literature DB >> 3493209

Suppression of pulmonary tumour metastasis in mice by recombinant human interleukin-2: role of asialo GM1-positive cells.

S Hinuma, K Naruo, K Ootsu, T Houkan, O Shiho, K Tsukamoto.   

Abstract

Recombinant human interleukin-2 (rIL-2) suppressed metastatic tumour colony formation in the lungs of C57BL/6 mice bearing Lewis lung carcinoma (3LL). In tumour-bearing mice given rIL-2, non-specific killer cells that were cytotoxic not only against natural killer-sensitive YAC-1 cells but also against 3LL cells in an in vitro 51Cr-release assay were concomitantly induced as tumour metastasis was suppressed. These non-specific killer cells were mostly removed by treatment with anti-Thy 1.2 or anti-asialo GM1 antibody plus complement (C) in vitro but not with anti-Lyt 1.2 or anti-Lyt 2.2 plus C, indicating that they were positive for Thy 1 and asialo GM1 but not for Lyt 1 and Lyt 2. In order to explore the mechanism by which rIL-2 suppressed tumour metastasis, we examined the clearance of intravenously injected 51Cr-labelled 3LL cells in the lungs of mice given rIL-2. The rate of tumour cell clearance was increased. This enhanced clearance was almost completely removed by injecting anti-asialo GM1 antibody. In addition, the injection of anti-asialo GM1 antibody also depleted most of the non-specific killer cells induced by administering rIL-2. These results indicate that asialo GM1-positive cells are not only cytotoxic in vitro but also play a critical role in the clearance of 3LL cells in the lungs in vivo. Our results indicate that asialo GM1-positive cells play an important role as anti-metastatic effector cells in suppressing the metastasis of 3LL cells in mice given rIL-2.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3493209      PMCID: PMC1453217     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  23 in total

1.  Selective in vitro growth of T lymphocytes from normal human bone marrows.

Authors:  D A Morgan; F W Ruscetti; R Gallo
Journal:  Science       Date:  1976-09-10       Impact factor: 47.728

2.  Studies of murine large granular lymphocytes. I. Identification as effector cells in NK and K cytotoxicities.

Authors:  K Kumagai; K Itoh; R Suzuki; S Hinuma; F Saitoh
Journal:  J Immunol       Date:  1982-07       Impact factor: 5.422

3.  Translation of interleukin 2 mRNA from human peripheral blood leukocytes in Xenopus oocytes.

Authors:  S Hinuma; H Onda; K Naruo; Y Ichimori; M Koyama; K Tsukamoto
Journal:  Biochem Biophys Res Commun       Date:  1982-11-30       Impact factor: 3.575

4.  In vivo effects of anti-asialo GM1. I. Reduction of NK activity and enhancement of transplanted tumor growth in nude mice.

Authors:  S Habu; H Fukui; K Shimamura; M Kasai; Y Nagai; K Okumura; N Tamaoki
Journal:  J Immunol       Date:  1981-07       Impact factor: 5.422

5.  In vivo administration of purified Jurkat-derived interleukin 2 in mice.

Authors:  J H Donohue; M T Lotze; R J Robb; M Rosenstein; R M Braziel; E S Jaffe; S A Rosenberg
Journal:  Cancer Res       Date:  1984-04       Impact factor: 12.701

6.  Natural killer (NK) cells as a responder to interleukin 2 (IL 2). I. Proliferative response and establishment of cloned cells.

Authors:  R Suzuki; K Handa; K Itoh; K Kumagai
Journal:  J Immunol       Date:  1983-02       Impact factor: 5.422

7.  Characteristics of murine non-specific killer cells induced in vivo by recombinant human interleukin-2.

Authors:  S Hinuma; K Naruo; O Shiho; K Tsukamoto
Journal:  Immunology       Date:  1986-10       Impact factor: 7.397

8.  Assessment of in vivo natural antitumor resistance and lymphocyte. Migration in mice: comparison of 125I-iododeoxyuridine with 111indium-oxine and 51chromium as cell labels.

Authors:  R H Wiltrout; E Gorelik; M J Brunda; H T Holden; R B Herberman
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

9.  Structure and expression of a cloned cDNA for human interleukin-2.

Authors:  T Taniguchi; H Matsui; T Fujita; C Takaoka; N Kashima; R Yoshimoto; J Hamuro
Journal:  Nature       Date:  1983 Mar 24-30       Impact factor: 49.962

10.  Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2.

Authors:  A Mazumder; S A Rosenberg
Journal:  J Exp Med       Date:  1984-02-01       Impact factor: 14.307

View more
  9 in total

1.  Detection and characterization of anti-tumour effector cells in Meth-A-bearing mice treated with recombinant human interleukin 2.

Authors:  K I Naruo; S Hinuma; O Shiho; T Houkan; K Ootsu; K Tsukamoto
Journal:  Clin Exp Immunol       Date:  1989-05       Impact factor: 4.330

2.  Therapeutic efficacy of human recombinant interleukin-2 (TGP-3) alone or in combination with cyclophosphamide and immunocompetent cells in allogeneic, semi-syngeneic, and syngeneic murine tumors.

Authors:  K Ootsu; K Gotoh; T Houkan
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

3.  Effect of recombinant human interleukin-2 on the course of experimental chronic respiratory tract infection caused by Klebsiella pneumoniae in mice.

Authors:  Y Iizawa; T Nishi; M Kondo; K Tsuchiya; A Imada
Journal:  Infect Immun       Date:  1988-01       Impact factor: 3.441

Review 4.  NK cells in the tumor microenvironment.

Authors:  Stine K Larsen; Yanhua Gao; Per H Basse
Journal:  Crit Rev Oncog       Date:  2014

5.  Elimination of CD4+ T cells in mice bearing an advanced sarcoma augments the antitumor action of interleukin-2.

Authors:  A L Rakhmilevich; R J North
Journal:  Cancer Immunol Immunother       Date:  1994-02       Impact factor: 6.968

6.  Functional visualization of NK cell-mediated killing of metastatic single tumor cells.

Authors:  Hiroshi Ichise; Shoko Tsukamoto; Tsuyoshi Hirashima; Yoshinobu Konishi; Choji Oki; Shinya Tsukiji; Satoshi Iwano; Atsushi Miyawaki; Kenta Sumiyama; Kenta Terai; Michiyuki Matsuda
Journal:  Elife       Date:  2022-02-03       Impact factor: 8.140

7.  Synergy of Nocardia rubra cell wall skeleton and interleukin 2 in the in vivo induction of murine lymphokine-activated killer cell activity.

Authors:  I Kawase; K Komuta; T Shirasaka; H Hara; Y Tanio; M Watanabe; S Saito; T Ikeda; T Masuno; S Kishimoto
Journal:  Jpn J Cancer Res       Date:  1989-11

8.  Combination therapy of colon carcinoma 26 in mice with recombinant human interleukin-2 and interferon-alpha A/D: occurrence of large granular cells in the tumor.

Authors:  Y Sakura; K Ootsu; A Shino
Journal:  Jpn J Cancer Res       Date:  1989-09

9.  Antitumor effect of recombinant human interleukin-2 on the growth of murine hemangioendothelioma D14 in nude mice: occurrence of large granular cells in the tumor.

Authors:  Y Sakura; T Houkan; K Ootsu; A Shino
Journal:  Jpn J Cancer Res       Date:  1991-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.